Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis von Crowley, J.J., Warren, R.B., Cather, J.C.

Volltext

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled tri... von Paul, C., Cather, J., Gooderham, M., Poulin, Y., Mrowietz, U., Ferrandiz, C., Crowley, J., Hu, C., Stevens, R.M., Shah, K., Day, R.M., Girolomoni, G., Gottlieb, A.B.

Volltext

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis von Papp, K.A., Reich, K., Paul, C., Blauvelt, A., Baran, W., Bolduc, C., Toth, D., Langley, R.G., Cather, J., Gottlieb, A.B., Thaçi, D., Krueger, J.G., Russell, C.B., Milmont, C.E., Li, J., Klekotka, P.A., Kricorian, G., Nirula, A.

Volltext

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)... von Paller, A.S., Seyger, M.M.B., Alejandro Magariños, G., Bagel, J., Pinter, A., Cather, J., Keller, S., Rodriguez Capriles, C., Gontijo Lima, R., Gallo, G., Little, C.A., Edson‐Heredia, E., Li, L., Xu, W., Papp, K.

Volltext

Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis von Ryan, C., Menter, A., Guenther, L., Blauvelt, A., Bissonnette, R., Meeuwis, K., Sullivan, J., Cather, J.C., Yosipovitch, G., Gottlieb, A.B., Merola, J.F., Callis Duffin, K., Fretzin, S., Osuntokun, O.O., Burge, R., Naegeli, A.N., Yang, F.E., Lin, C.‐Y., Todd, K., Potts Bleakman, A.

Volltext

Cannabidiol primer for healthcare professionals von Cather, Jennifer Clay, Cather, J. Christian

Volltext

Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials von Guenther, L., Warren, R.B., Cather, J.C., Sofen, H., Poulin, Y., Lebwohl, M., Terui, T., Potts Bleakman, A., Zhu, B., Burge, R., Reich, K., Kerkhof, P.

Volltext

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab von Cather, Jennifer Clay, Cather, J Christian, Menter, Alan

Volltext

Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vβ gene expansion von JACKOW, C. M, CATHER, J. C, HEARNE, V, ASANO, A. T, MUSSER, J. M, DUVIC, M

Volltext

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, plac... von Blauvelt, Andrew, Dr, de Bruin-Weller, Marjolein, MD, Gooderham, Melinda, MD, Cather, Jennifer C, MD, Weisman, Jamie, MD, Pariser, David, Prof, Simpson, Eric L, Prof, Papp, Kim A, MD, Hong, H Chih-Ho, MD, Rubel, Diana, MD, Foley, Peter, MD, Prens, Errol, Prof, Griffiths, Christopher E M, Prof, Etoh, Takafumi, MD, Pinto, Pedro Herranz, MD, Pujol, Ramon M, MD, Szepietowski, Jacek C, Prof, Ettler, Karel, MD, Kemény, Lajos, Prof, Zhu, Xiaoping, PhD, Akinlade, Bolanle, MD, Hultsch, Thomas, MD, Mastey, Vera, MS, Gadkari, Abhijit, PhD, Eckert, Laurent, PhD, Amin, Nikhil, MD, Graham, Neil M H, MD, Pirozzi, Gianluca, MD, Stahl, Neil, PhD, Yancopoulos, George D, MD, Shumel, Brad, MD

Volltext

Efficacy and safety of ixekizumab in a phaseIII, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) von Paller, A. S., Seyger, M. M. B., Alejandro Magarinos, G., Bagel, J., Pinter, A., Cather, J., Keller, S., Rodriguez Capriles, C., Gontijo Lima, R., Gallo, G., Little, C. A., Edson-Heredia, E., Li, L., Xu, W., Papp, K.

Volltext

Ichthyosiform sarcoidosis von CATHER, J. C, COHEN, P. R

Volltext

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial von Papp, Kim, Dr, Cather, Jennifer C, MD, Rosoph, Les, MD, Sofen, Howard, MD, Langley, Richard G, MD, Matheson, Robert T, MD, Hu, ChiaChi, EdM, Day, Robert M, PhD

Volltext

L’apremilast dans le psoriasis en plaques modéré à sévère : résultats à 32 semaines sur l’atteinte unguéale, palmo-plantaire et du cuir chevelu (ESTEEM 2) von Crowley, J., Cather, J., Gooderham, M., Sebastian, M., Girolomoni, G., Ferrandiz, C., ChiaChi, H., Day, R.M., Beylot-Barry, M.

Volltext

Hypertrophic and atrophic scars von Cather, J Christian, Cather, Jennifer Clay

Volltext

Ixekizumab efficacy and safety in moderate‐to‐severe genital psoriasis von Ryan, C., Menter, A., Guenther, L., Blauvelt, A., Bissonnette, R., Meeuwis, K., Sullivan, J., Cather, J.C., Yosipovitch, G., Gottlieb, A.B., Merola, J.F., Callis Duffin, K., Fretzin, S., Osuntokun, O.O., Burge, R., Naegeli, A.N., Yang, F.E., Lin, C.‐Y., Todd, K., Potts Bleakman, A.

Volltext

Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma von Cather a, Jennifer Clay, Farmer a, Amy, Jackow a, Clotilde, Manning d, John T., Shin e, Dong M., Duvic a,b,c, Madeleine

Volltext

Mycosis fungoides with focal segmental glomerular sclerosis and nephrotic syndrome von Cather, Jennifer Clay, Jackow, Clotilde, Yegge, James, Hagemeister, Frederick, Duvic, Madeleine

Volltext

Efficacité et tolérance de l’apremilast, inhibiteur oral de la phosphodiestérase 4, dans le psoriasis modéré à sévère (ESTEEM 2) : résultats à 16 semaines d’une étude de phase III... von Paul, C., Ferrandiz, C., Cather, J., Gooderham, M., Poulain, Y., Mrowietz, U., Crowley, J., Hu, C., Stevens, R., Day, R., Giromoloni, G.

Volltext

A child with nonscarring alopecia von Cather, J Christian, Cather, Jennifer Clay

Volltext